Amgen and Takeda will join fellow big pharma companies Sanofi, GSK, and Janssen, in working to progress Feldan’s intracellular drug delivery technology.
Aldevron announces the expansion of its headquarters’ campus by half a million-square-feet, which will see annual capacity exceed $1bn of biologic products.
Fujifilm Life Science Strategic Business Office will open a site in Cambridge, Massachusetts in an aim to further link up with the surrounding pharmaceutical and biotech community.
Thermo Fisher and Scinogy partner to improve scalability and cost-effectiveness of cell and gene therapy manufacture through the addition of the former’s centrifuge.
Bluebird has received EU conditional marketing approval for patients with transfusion-dependent β-thalassemia, becoming the first treatment from its pipeline to receive approval.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
In the UK alone, the numbers of employees entering the cell and gene therapy manufacturing space needs to double in the next five years, eXmoor’s MD suggested.
Novo Holdings invests £53.5m in Oxford Biomedica, funds which the company will use to further develop its LentiVector platform for cell and gene therapies.
Evotec to join the emerging biologics market through Just Biotherapeutics’ smart technology platforms, machine learning tools and low cost manufacturing facilities.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
